BRUSSELS, Belgium, June 26, 2026 (BSS/AFP) - The European Commission 
announced Friday that it was opening an antitrust probe into French 
pharmaceutical group Sanofi on suspicion it breached the bloc's competition 
rules in promoting a flu vaccine.

The probe centres on how the firm marketed an enhanced flu vaccine, offered 
under the brand name Efluelda and designed to provide greater protection for 
people over 60.

The vaccine in question competes with one marketed by the Australian company 
CSL Seqirus under the brand name Fluad.

"The commission is concerned that Sanofi pursued a misleading communication 
campaign to disparage Fluad by portraying it as inferior to Efluelda, going 
against national vaccination recommendations in several member states," a 
commission statement said.

The EU executive, acting as the bloc's competition watchdog, said the 
campaign primarily targeted healthcare professionals in Germany and France, 
where Sanofi is considered to hold a dominant position.

Sanofi had revealed last September that it was being investigated by the EU 
over its practices in the hugely competitive flu vaccine sector.

Contacted by AFP, the group denied breaking EU rules.

"Sanofi is confident that it has acted, and continues to act, in full 
compliance with all applicable laws and regulations, including competition 
rules," a company spokeswoman said.

She called the EU inquiry "a procedural step" that "does not in any way 
prejudge the outcome of the investigation".

"Sanofi remains committed to fair competition and to maintaining patient 
access to innovative vaccines," she added.

Flu vaccines are a major business for Sanofi, whose products are widely 
administered as part of annual national vaccination campaigns in France in 
particular.

Aside from CSL Seqirus, its main competitors include the US company Viatris.

If the alleged anticompetitive practices are confirmed, the commission could 
impose a penalty on Sanofi for abuse of a dominant position, in the form of a 
fine.

As part of the proceedings, Sanofi could also offer commitments to address 
the commission's concerns.